Injections of monoclonal antibodies (mAb) blocking immunological checkpoints, such as CTLA-4, PD-1, and PD-L1, enhance antitumor immunity and lead to tumor rejection [3,4,5,6]. The gene discussed is PDCD1; the disease is neoplasm.